EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab By Ogkologos - May 8, 2026 93 0 Facebook Twitter Google+ Pinterest WhatsApp It is a cancer medicine used to treat adult patients with multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Tepotinib December 23, 2021 EMA Recommends Granting a Marketing Authorisation for Acalabrutinib July 30, 2020 Meet Rosalie: St. Jude Children’s Research Hospital’s New Service Dog For... October 19, 2021 Giving Birth Before Age 20 Cuts Breast Risk By 50%, And... December 12, 2019 Load more HOT NEWS Intratumoural Administration of the Oncolytic Herpes Virus Shows Survival Benefit and... Teen Gets Bullied After Series Of Drastic Growth Spurts, Now She... Satisfying Snacks Shannen Doherty Reveals She Has Stage IV Breast Cancer
